Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

医学 彭布罗利珠单抗 三阴性乳腺癌 化疗 肿瘤科 乳腺癌 癌症 内科学 免疫疗法
作者
Javier Cortés,Hope S. Rugo,David W. Cescon,Seock‐Ah Im,Mastura Md Yusof,Carlos Gallardo,Oleg Lipatov,Carlos H. Barrios,José Manuel Pérez-García,Hiroji Iwata,Norikazu Masuda,Marco Torregroza Otero,Erhan Gokmen,Sherene Loi,Zifang Guo,Xuan Zhou,Vassiliki Karantza,Wilbur Pan,Peter Schmid
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:387 (3): 217-226 被引量:1409
标识
DOI:10.1056/nejmoa2202809
摘要

BACKGROUND: In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS; the number of PD-L1-staining tumor cells, lymphocytes, and macrophages, divided by the total number of viable tumor cells, multiplied by 100) of 10 or more. The results of the final analysis of overall survival have not been reported. METHODS: We randomly assigned patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer in a 2:1 ratio to receive pembrolizumab (200 mg) every 3 weeks plus the investigator's choice of chemotherapy (nanoparticle albumin-bound paclitaxel, paclitaxel, or gemcitabine-carboplatin) or placebo plus chemotherapy. The primary end points were progression-free survival (reported previously) and overall survival among patients whose tumors expressed PD-L1 with a CPS of 10 or more (the CPS-10 subgroup), among patients whose tumors expressed PD-L1 with a CPS of 1 or more (the CPS-1 subgroup), and in the intention-to-treat population. Safety was also assessed. RESULTS: A total of 847 patients underwent randomization: 566 were assigned to the pembrolizumab-chemotherapy group, and 281 to the placebo-chemotherapy group. The median follow-up was 44.1 months. In the CPS-10 subgroup, the median overall survival was 23.0 months in the pembrolizumab-chemotherapy group and 16.1 months in the placebo-chemotherapy group (hazard ratio for death, 0.73; 95% confidence interval [CI], 0.55 to 0.95; two-sided P = 0.0185 [criterion for significance met]); in the CPS-1 subgroup, the median overall survival was 17.6 and 16.0 months in the two groups, respectively (hazard ratio, 0.86; 95% CI, 0.72 to 1.04; two-sided P = 0.1125 [not significant]); and in the intention-to-treat population, the median overall survival was 17.2 and 15.5 months, respectively (hazard ratio, 0.89; 95% CI, 0.76 to 1.05 [significance not tested]). Adverse events of grade 3, 4, or 5 that were related to the trial regimen occurred in 68.1% of the patients in the pembrolizumab-chemotherapy group and in 66.9% in the placebo-chemotherapy group, including death in 0.4% of the patients in the pembrolizumab-chemotherapy group and in no patients in the placebo-chemotherapy group. CONCLUSIONS: Among patients with advanced triple-negative breast cancer whose tumors expressed PD-L1 with a CPS of 10 or more, the addition of pembrolizumab to chemotherapy resulted in significantly longer overall survival than chemotherapy alone. (Funded by Merck Sharp and Dohme; KEYNOTE-355 ClinicalTrials.gov number, NCT02819518.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Patman发布了新的文献求助10
刚刚
余香的应助被yjh采纳,获得10
刚刚
文静凝旋完成签到,获得积分10
刚刚
Owen的应助被认真连虎采纳,获得10
1秒前
1秒前
楚司遥完成签到,获得积分10
1秒前
1秒前
pinst7完成签到,获得积分10
2秒前
易瑾完成签到 ,获得积分10
2秒前
DW的应助被悦耳的尔冬采纳,获得10
2秒前
luoll发布了新的文献求助10
2秒前
2秒前
科研通AI2S的应助被111采纳,获得10
2秒前
3秒前
3秒前
张天虹完成签到,获得积分10
3秒前
zcydbttj2011完成签到 ,获得积分10
3秒前
3秒前
piglet完成签到,获得积分10
3秒前
leotao发布了新的文献求助10
3秒前
4秒前
4秒前
小露发布了新的文献求助10
4秒前
Christoph_Lee完成签到,获得积分10
4秒前
paek完成签到,获得积分10
4秒前
瓦伦泰完成签到 ,获得积分10
5秒前
5秒前
Laura发布了新的文献求助30
5秒前
仲康康完成签到,获得积分10
5秒前
ding的应助被慕豁采纳,获得10
5秒前
科研通AI2S的应助被Lucas采纳,获得10
5秒前
5秒前
5秒前
李爱国的应助被ZS采纳,获得10
6秒前
jerkran完成签到,获得积分10
6秒前
6秒前
6秒前
吹泡泡完成签到,获得积分10
7秒前
quanchengBjcp完成签到,获得积分20
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180807
求助须知:如何正确求助?哪些是违规求助? 9570895
关于积分的说明 21815089
捐赠科研通 7777155
什么是DOI,文献DOI怎么找? 3433347
关于科研通互助平台的介绍 2557613
邀请新用户注册赠送积分活动 2479317